8/4/2014 10:56:41 AM
MORRISTOWN, N.J.--(BUSINESS WIRE)--Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced that the closing of its transaction to acquire the U.S. rights to Treximet® (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults has been delayed due to a short-term supply constraint for the product. The Company is working with GlaxoSmithKline to ensure sufficient supply to meet anticipated demand. The Company and its lenders are also performing additional due diligence related to this supply issue.
Help employers find you! Check out all the jobs and post your resume.
comments powered by